Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )
Status:
Unknown status
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
Clinical studies related to immunotherapy of HNSCC have shown that PD1 monoclonal antibody
has better clinical benefits than conventional chemotherapy. This phase II clinical study is
a single arm, open, single-center study. The aim of this study is to observe and evaluate the
efficacy and safety of Sintilimab combined with paclitaxel-albumin-binding for injection in
patients with advanced recurrent and metastatic HNSCC who fail to receive first-line or more
treatment. Participation in this study for treatment may benefit patients with advanced
recurrence or metastasis of HNSCC.